Clinical Oncology Next-generation Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Clinical Oncology Next-generation Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : October, 2020 | Biotechnology | PPT format

Report Digest


Global Clinical Oncology Next-generation Sequencing Market: Snapshot

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization. It is otherwise called high throughput sequencing. The innovation limits the need for section cloning which is utilized in Sanger sequencing of genomes. The key benefits that NGS offers over Sanger's sequencing technique are swift processes, precise results, and ease of operations even from low sample inputs. With the advancement of new technologies and treatment to cure cancer, the clinical oncology next generation sequencing market has enormous potential in coming years.

The significant explanation that is driving the development of the clinical oncology next generation sequencing market are the decrease in the expense of capital and sequencing and improved administrative conditions & repayment for NSG diagnostics. Likewise, the expanding use of precision drugs and molecular diagnostics alongside proposition of huge sequencing ventures by government and private sector are few more factors that are driving the growth of clinical oncology next generation sequencing market.

Some of the Recent Developments in Global Clinical Oncology Next Generation Sequencing Market?

  • In 2019, Agilent Technologies, a leader in global clinical oncology-next generation sequencing market acquired BioTek Instruments. The acquisition aims to enhance the production capacity of company and research and development that shall help the company to major share of the global clinical oncology-next generation sequencing market. This shall also allow the company to gain access to the latest technologies of the BioTek making it one of most prominent company in the global clinical oncology-next generation sequencing market.

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization. It is otherwise called high throughput sequencing. The innovation limits the need for section cloning which is utilized in Sanger sequencing of genomes. The key benefits that NGS offers over Sanger's sequencing technique are swift processes, precise results, and ease of operations even from low sample inputs. With the advancement of new technologies and treatment to cure cancer, the clinical oncology next generation sequencing market has enormous potential in coming years.

The significant explanation that is driving the development of the clinical oncology next generation sequencing market are the decrease in the expense of capital and sequencing and improved administrative conditions & repayment for NSG diagnostics. Likewise, the expanding use of precision drugs and molecular diagnostics alongside proposition of huge sequencing ventures by government and private sector are few more factors that are driving the growth of clinical oncology next generation sequencing market.

Some of the Recent Developments in Global Clinical Oncology Next Generation Sequencing Market?

  • In 2019, Agilent Technologies, a leader in global clinical oncology-next generation sequencing market acquired BioTek Instruments. The acquisition aims to enhance the production capacity of company and research and development that shall help the company to major share of the global clinical oncology-next generation sequencing market. This shall also allow the company to gain access to the latest technologies of the BioTek making it one of most prominent company in the global clinical oncology-next generation sequencing market.

Global Clinical Oncology Next-generation Sequencing Market – Overview

Next generation sequencing is also known as non-Sanger based high throughput DNA sequencing technology. This term is particularly used for defining advanced and modern sequencing technologies such as Roche 454 Sequencing, Illumina (Solexa) Sequencing, Proton/PGM sequencing, and SOLiD sequencing among others. Billions of DNA strands are chained in parallel that provide considerable more throughput. The clinical oncology-next generation sequencing market is thus making use of such new sequencing technologies for profiling cancer. The leading players in the global market are concentrating more on acquisitions, mergers, and strategic joint ventures. This has thus helped the developing nations to offer support to set up new centers for research and development activities.

Global Clinical Oncology Next-generation Sequencing Market – Notable Developments

Some of the notable developments in the global clinical oncology-next generation sequencing market are given below:

  • In April 2017, Genomatix Inc. announced that the company has successfully acquired funding from the Bavarian Ministry of Economic Affairs and Media, Energy, and Technology for the Multiple Integration and Data Annotation Study (MIDAS) project. The aim of the project and funding is to enhance the characterization of rare diseases such as cancer in children and devise effective treatment.
  • In August 2019, Agilent Technologies, a prominent name in the global clinical oncology-next generation sequencing market announced that the company has successfully taken over BioTek Instruments. This acquisition is expected to bolster the production capacity of Agilent Technologies. The aim of the acquisition was to complement the research in the field of next generation sequencing by developing effective technologies for the same.

Some of the leading vendors in the global next-generation sequencing market are: 

  • GATC Biotech Ag
  • Oxford Nanopore Technologies Ltd.
  • Macrogen Inc.
  • Life technologies Corp.
  • DNASTAR Inc.
  • Myriad Genetics
  • Exosome Diagnostics
  • Biomatters Ltd.
  • BGI (Beijing Genomics Institute)
  • Qiagen NV, Perkin Elmer, Inc.
  • Pacific Bioscience, Inc.
  • Partek, Inc.
  • Bio-Rad Laboratories, Inc.

Global Clinical Oncology Next-generation Sequencing Market – Drivers and Restraints

Among the several growth influencing factors for the clinical oncology-next generation sequencing market, the biggest factor is the increasing adoption of genomic-centric pharmacology in the treatment of cancer. The clinical oncology-next generation sequencing market makes use of the most advanced genomic techniques and technologies to investigate the genetic changes that occur due to the spreading of cancer in the body. The rapid development and innovations in this segment is thus driving the overall growth of the global clinical oncology-next generation sequencing market.

In addition to this, there has been a considerable rise in investments and funding to the research and development centers concentrating on finding new solutions in sequencing. This factor coupled with expanding healthcare budgets of several developed nations is also providing a big help to the global clinical oncology-next generation sequencing market.

Moreover, the practicing medical professionals and doctors are now familiar with clinical oncology-next generation sequencing and are increasingly using the same for diagnosis and treatment of cancer. This has not only spreading the awareness among the common masses but also helping to scale up the uptake of the global market. Oncologists these days are more reliant clinical oncology-next generation sequencing to select drugs or their combination for treating patients.

Global Clinical Oncology Next-generation Sequencing Market – Geographical Outlook

There are five main geographical segments of the global clinical oncology-next generation sequencing market viz. Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Of these, the global market is expected to be dominated by North America over the course of the given forecast period of 2018 to 2028. This growth of the market is due to heavy spending on the development of new R&D facilities that work on clinical oncology-next generation sequencing. In addition to this, the presence of several leading players in the global market has also worked in favor for the growth of the North America market.

Global Clinical Oncology Next-generation Sequencing Market Segmentation:

Product Type

  • NGS Pre-Sequencing
  • Sequencing
  • NGS Data Analysis
  • Primary, Secondary & Tertiary Data Analysis

Application

  • Academic & Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities

This study provides a particularized anatomy according to the L.E.A.P mechanism

  • Latest trends and cardinal growth prospects
  • Existing and future insights in growth
  • Ascensions in technology
  • Pain points

The regional analysis offers market assays across:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.

Latest Trends and Cardinal Growth Prospects

The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.

Existing and Future Insights in Growth

The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.

Ascensions in Technology

Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.

Pain Points

The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.

The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.

An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.

The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!

This report is the key to questions such as:

What are the prominent factors that will help in reshaping the market growth?

Which trends have the potential to bring expansive growth for the market?

What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?

Which regions will emerge as champion growth contributors for the market?

Which aspects will serve as game-changers for the market?

What are the latest innovations in the market?

Which factors will hinder the growth of the market?